Form 4: United Therapeutics' President and COO, Michael Benkowitz, Executes Stock Options and Sells Shares Under 10b5-1 Plan

Michael Benkowitz, President and COO of United Therapeutics, executed stock options and sold shares of common stock on January 27, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On January 27, 2025, Michael Benkowitz, the President and COO of United Therapeutics, exercised stock options and sold shares of the company's common stock.
• These transactions were executed under a Rule 10b5-1 trading plan that Benkowitz entered into on August 7, 2024.
• The sales were conducted in multiple trades at varying prices, with weighted average prices reported for each set of transactions.
• The shares were held in trusts beneficially owned by Benkowitz, with different levels of investment and voting power depending on the trust.
• Benkowitz has committed to providing full information regarding the number of shares and prices at which each transaction was effected upon request.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions by an executive. The transactions were pre-planned under a 10b5-1 plan, so they don't necessarily reflect the executive's current sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 plans to manage their stock holdings and avoid accusations of insider trading. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the number of shares outstanding, but the effect is likely minimal given the volume of shares traded daily.

Key Dates